These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 32452702)

  • 1. Pharmacotherapeutic management of lower urinary tract symptoms in Multiple Sclerosis patients.
    Zanghì A; Cimino S; Urzì D; Privitera S; Zagari F; Lanza G; Patti F; D'Amico E
    Expert Opin Pharmacother; 2020 Aug; 21(12):1449-1454. PubMed ID: 32452702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of the implantable, magnetic resonance imaging-compatible StimRouter neuromodulation system in the treatment of refractory lower urinary tract symptoms in multiple sclerosis patients.
    Sacco R; Maino P; Koetsier E; Disanto G; Renard J; Digesu A; Gobbi C; Zecca C
    Eur J Neurol; 2024 Feb; 31(2):e16146. PubMed ID: 37975785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders.
    Mangera A; Apostolidis A; Andersson KE; Dasgupta P; Giannantoni A; Roehrborn C; Novara G; Chapple C
    Eur Urol; 2014 May; 65(5):981-90. PubMed ID: 24239446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sacral neuromodulation: an effective treatment for lower urinary tract symptoms in multiple sclerosis.
    Puccini F; Bhide A; Elneil S; Digesu GA
    Int Urogynecol J; 2016 Mar; 27(3):347-54. PubMed ID: 26156206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Which clinical risk factors determine a pathological urodynamic evaluation in patients with multiple sclerosis? an analysis of 100 prospective cases.
    Wiedemann A; Kaeder M; Greulich W; Lax H; Priebel J; Kirschner-Hermanns R; Füsgen I
    World J Urol; 2013 Feb; 31(1):229-33. PubMed ID: 22227822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
    Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
    Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lower Urinary Tract Symptoms: What's New in Medical Treatment?
    Peyronnet B; Brucker BM; Michel MC
    Eur Urol Focus; 2018 Jan; 4(1):17-24. PubMed ID: 29665997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The diagnosis and management of lower urinary tract symptoms in multiple sclerosis patients.
    Sand PK; Sand RI
    Dis Mon; 2013 Jul; 59(7):261-8. PubMed ID: 23786660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vesicourethral dysfunction in multiple sclerosis. Initial assessment based on lower urinary tract symptoms and their pathophysiology.
    Di Benedetto P; Delneri C; Biasutti E; Bragadin LM; Giorgini T
    Neurol Sci; 2008 Dec; 29 Suppl 4():S348-51. PubMed ID: 19089674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of lower urinary tract symptoms in patients with idiopathic normal pressure hydrocephalus.
    Krzastek SC; Bruch WM; Robinson SP; Young HF; Klausner AP
    Neurourol Urodyn; 2017 Apr; 36(4):1167-1173. PubMed ID: 27490149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Botulinum toxin treatment for bladder dysfunction.
    Santos-Silva A; da Silva CM; Cruz F
    Int J Urol; 2013 Oct; 20(10):956-62. PubMed ID: 23634720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of neurogenic lower urinary tract symptoms: main contributions from 2018 and 2019.
    Abreu-Mendes P; Cruz F; Martins-Silva C
    Curr Opin Urol; 2020 Jul; 30(4):486-490. PubMed ID: 32398466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic outcome and quality of life between urethral and detrusor botulinum toxin treatment for patients with spinal cord lesions and detrusor sphincter dyssynergia.
    Kuo HC
    Int J Clin Pract; 2013 Oct; 67(10):1044-9. PubMed ID: 24073977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protocol for a prospective observational study of cortical lower urinary tract control changes following intradetrusor injection of botulinum toxin-A in patients with multiple sclerosis.
    Elizondo RA; Karmonik C; Boone TB; Khavari R
    BMJ Open; 2017 Feb; 7(2):e013225. PubMed ID: 28159850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Botulinum toxin injection for lower urinary tract dysfunction.
    Kuo YC; Kuo HC
    Int J Urol; 2013 Jan; 20(1):40-55. PubMed ID: 22571329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can we predict detrusor overactivity in women with lower urinary tract symptoms? The King's Detrusor Overactivity Score (KiDOS).
    Giarenis I; Musonda P; Mastoroudes H; Robinson D; Cardozo L
    Eur J Obstet Gynecol Reprod Biol; 2016 Oct; 205():127-32. PubMed ID: 27592416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lower urinary tract dysfunction in MS: management in the community.
    Panicker J; Haslam C
    Br J Community Nurs; 2009 Nov; 14(11):474, 476, 478-80. PubMed ID: 20166471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of fesoterodine fumarate (8 mg) in neurogenic detrusor overactivity due to spinal cord lesion or multiple sclerosis: A prospective study.
    Konstantinidis C; Samarinas M; Tzitzika M; Kratiras Z; Panagiotakopoulos G; Giannitsas K; Athanasopoulos A
    Neurourol Urodyn; 2021 Nov; 40(8):2026-2033. PubMed ID: 34498773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Propiverine: a review of its use in the treatment of adults and children with overactive bladder associated with idiopathic or neurogenic detrusor overactivity, and in men with lower urinary tract symptoms.
    McKeage K
    Clin Drug Investig; 2013 Jan; 33(1):71-91. PubMed ID: 23288694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity [corrected] regardless of concomitant anticholinergic use or neurologic etiology.
    Ginsberg D; Cruz F; Herschorn S; Gousse A; Keppenne V; Aliotta P; Sievert KD; Brin MF; Jenkins B; Thompson C; Lam W; Heesakkers J; Haag-Molkenteller C
    Adv Ther; 2013 Sep; 30(9):819-33. PubMed ID: 24072665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.